Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway

BACKGROUND: Palbociclib, a specific inhibitor of CDK4/6, has been shown to provide a survival benefit in hormone receptor-positive advanced breast cancer; however, its resistance and related mechanisms are unclear. MATERIAL/METHODS: In this study, we constructed palbociclib-resistant hormone recepto...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Med Sci Monit
Hlavní autoři: Chen, Lin, Yang, Guangsheng, Dong, Hongming
Médium: Artigo
Jazyk:Inglês
Vydáno: International Scientific Literature, Inc. 2019
Témata:
Lab/In Vitro Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6327776/
https://ncbi.nlm.nih.gov/pubmed/30605443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.912929
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky